Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean. In ...

A recent study reveals a surge in the use of GLP-1 medications, such as Ozempic and Wegovy, among younger age groups.

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

The benefit could nudge more Evernorth clients to cover GLP-1s. Currently, only half of its employer clients cover drugs like Wegovy and Zepbound for weight management, executives said on a call ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says. Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock ...

Evernorth said in an announcement that through its Express Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap ...

New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.